PROSTACOX : Metastatic Prostate Chemotherapy

Efficacy of Docetaxel (J 15) and Celecoxib in Metastatic Prostate Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00213694

Enrollment

Registered

2005-09-21

Start date

2003-11-30

Completion date

2006-06-30

Last updated

2013-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Prostate Cancer

Brief summary

Clinical response to chemotherapy. Biological parameter (PSA) and RECIST evaluation. Association of Docetaxel (J 15) and Celecoxib.

Detailed description

Association Docetaxel (J 15) and celecoxib Patient survival Biological parameter : PSA Clinical status RECIST evaluation

Interventions

DRUGdocetaxel and celecoxib

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Healthy volunteers

Inclusion criteria

* metastatic prostate cancer * ASCO progression criteria

Exclusion criteria

* other prostate chemotherapy

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026